- In-Stent Restenosis (ISR)
- Interventional Cardiology (IC)
- Coronary Artery Disease (CAD)
- Drug-Coated Balloon (DCB)
- Balloon Angioplasty
- Drug-Eluting Stent (DES)
Coronary drug-eluting balloon technology continues to evolve, but has its utilization been stunted by stenting? In this episode, Dr. Sameh Sayfo, an interventional cardiologist, hosts Dr. Ron Waksman, an internationally recognized cardiologist and scientist, to discuss advancements in coronary interventions and the age-old question of which coronary revascularization tools to use in which clinical scenarios.
Timestamps
Resources
- Dr. Sameh Sayfo
- Dr. Ron Waksman
- De Novo Trial, Drug-Coated Balloon for De Novo Coronary Artery Disease: Journal of American College of Cardiology State-of-the-Art Review
- The AGENT IDE Randomized Clinical Trial, Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial
More about this episode
Dr. Waksman shares his 30-year journey in the field, detailing the history and transition from traditional balloon angioplasty to drug-eluting stents, and now to drug-coated balloons. They explore the benefits and challenges of each technology, the significance of vessel preparation, and the latest trials, including the De Novo Trial led by Dr. Waksman. The conversation also touches on the importance of physician education and proper training in adopting new technologies. Additionally, Dr. Waksman provides insights into his approach to conducting interviews with notable public figures and hints at future discussions at the CRT annual meeting, potentially featuring President Biden.